BMRA News and Press, Biomerica Inc.

inFoods ® IBS patients can now conveniently self-collect a blood sample using a simple finger-stick methodology in the privacy of their home inFoods ® IBS test is the first of its kind to identify specific foods that can trigger an Irritable Bowel Syndrome (I...

Biomerica (NASDAQ: BMRA) , a biomedical technology company that develops, patents, manufactures and markets advanced diagnostics and therapeutic products, has entered into an at-market issuance sales agreement with EF Hutton LLC and R.F. Lafferty & Co. Inc. According to the company, the agree...

With IBS affecting 10 to 15% of the global population, the associated $21 billion in direct medical costs and absenteeism underscores the urgent need of innovative solutions. Recognized as the 7th most common diagnosis by all physicians, IBS represents a significant healthcare burden. inF...

2024-04-29 08:53:42 ET More on Biomerica Financial information for Biomerica Read the full article on Seeking Alpha For further details see: Biomerica jumps on signing multi-year distribution deal with major UAE healthcare company

Dubai Healthcare Authority Granted Insurance Reimbursement for Biomerica’s EZ Detect™ Colon Disease Screening Test EZ Detect ™ is a simple FDA cleared 2-minute at-home test that detects early warning signs of colorectal cancer, the third most common cancer...

- Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas. - Average quarterly increase in p hysicians prescribing i nFoods more than doubled each quarter over the past 12 months. - Bio...

2024-04-15 00:53:47 ET More on Biomerica Financial information for Biomerica Read the full article on Seeking Alpha For further details see: Biomerica GAAP EPS of -$0.11, revenue of $1M

Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst Sales Force Expansion for the Nine Months in Fiscal 2024 InFoods IBS Positive Clinical Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference in the DDW Irritable Bowel Syn...

Magna-Lab Inc. - Class A (YBGJ) is expected to report for quarter end 2023-12-31 Biomerica Inc. (BMRA) is expected to report for Q3 2024 EXPRESS INC. DL-01 (02Z0:DU) is expected to report $-8.99 for Q4 2024 Progressive Corporation (The) (PGR) is expected to report $3.18 for Q1 2024 ...

Collaborators at the University of Michigan will present new Data on InFoods ® IBS in the DDW Irritable Bowel Syndrome (IBS) Clinical Session IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company at the forefront ...